Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
PaperCitations, authors & open-access status
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)* is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 612 citations, 2020 year and hybrid oa status.
612
Citations
2020
Year
hybrid
OA Status